Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carol Harris

Interventional Pain Medicine Meridian, MS Medical Doctor

NPI 1710935671 CMS profile 214377

1314 19Th Ave, Meridian, MS 39301

Open in the dashboard

General payments

$3,516

50 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carol Harris of Meridian, MS is reported in the CMS Open Payments database as having received $3,516 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,486 11
2022 General $94 5
2021 General $186 5
2020 General $308 13
2019 General $442 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Harris
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Carol Harris were reported at $2,486. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Carol Harris Interventional Pain Medicine median Middle half National median
2019 $442 $684 $216–$2,079 $163
2020 $308 $382 $122–$1,109 $114
2021 $186 $552 $167–$1,554 $132
2022 $94 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $2,486 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $2,406 8 payments
  2. Abbott Laboratories $463 14 payments
  3. Medtronic USA, Inc. $167 7 payments
  4. Daiichi Sankyo Inc. $97 2 payments
  5. Averitas Pharma Inc. $80 3 payments
  6. Scilex Pharmaceuticals Inc. $73 1 payment
  7. Nevro Corp. $54 4 payments
  8. GRT US Holding, Inc. $43 3 payments
  9. Boston Scientific Corporation $42 2 payments
  10. RedHill Biopharma Inc. $32 2 payments
  11. Other $60 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,155 4 payments
  2. Food and Beverage $1,361 46 payments
Products named General payments · program years 2019–2025
  1. Iovera $2,406 8 payments
  2. Proclaim Family of SCS IPGs $263 9 payments
  3. Proclaim IPG $161 3 payments
  4. INTELLIS $153 6 payments
  5. Qutenza $123 6 payments
  6. Morphabond ER $97 2 payments
  7. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $73 1 payment
  8. Senza Spinal Cord Stimulation System $54 4 payments
  9. PROCLAIM $39 2 payments
  10. Movantik $32 2 payments
  11. Other $178 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

2,124

Median for Pain Management: 951

Drug cost

$38,122

Median for Pain Management: $26,034

Branded share of claims

49.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 838 $17,607
Gabapentin Generic 351 $4,424
Buprenorphine Generic 13 $3,678
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 76 $2,143
Pregabalin Generic 69 $1,454
Tizanidine Hcl Generic 138 $1,399
Acetaminophen-Codeine Acetaminophen With Codeine Brand 123 $1,365
Diclofenac Sodium Generic 23 $1,127
Cyclobenzaprine Hcl Generic 83 $838
Tramadol Hcl Er Tramadol Hcl Brand 15 $745

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$47,085

Medicare's payments for the services billed

Medicare patients

318

Average age 70

Services billed

615

197 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Chronic kidney disease 32%
Depression 32%
Ischemic heart disease 31%
COPD 27%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record